This hottest twist inside the Lykos Therapeutics saga threatens a major overhaul of the corporation’s system and course, with Musk ally and billionaire investor Antonio Gracias showing to wish to consider the business back towards its nonprofit drug development roots and a more Doblinite philosophy.In several respects, the for-income copyright di